{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/KALV/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T01:26:21.160Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9761,"canonical_name":"KalVista Pharmaceuticals, Inc.","cik":"0001348911","uei":null,"lei":null,"duns":null,"ticker":"KALV"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":60,"clinical":1},"count":61,"timeline":[{"ts":"2026-08-11","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — KalVista Pharmaceuticals, Inc. — 2026-08-11","url_slug":"/sec/cik-0001348911/schedule-13g/0001104659-26-093853","accession_number":"0001104659-26-093853","importance":55},{"ts":"2026-06-22","kind":"sec.filing","form_type":"15-12G","title":"15-12G — KalVista Pharmaceuticals, Inc. — 2026-06-22","url_slug":"/sec/cik-0001348911/15-12g/0001140361-26-025858","accession_number":"0001140361-26-025858","importance":30},{"ts":"2026-06-16","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — KalVista Pharmaceuticals, Inc. — 2026-06-16","url_slug":"/sec/cik-0001348911/effect/9999999995-26-002005","accession_number":"9999999995-26-002005","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"8-K","title":"8-K — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/8-k/0001140361-26-024949","accession_number":"0001140361-26-024949","importance":35},{"ts":"2026-06-11","kind":"sec.filing","form_type":"25-NSE","title":"25-NSE — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/25-nse/0001354457-26-000565","accession_number":"0001354457-26-000565","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001366244-26-000012","accession_number":"0001366244-26-000012","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001492749-26-000002","accession_number":"0001492749-26-000002","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001594774-26-000002","accession_number":"0001594774-26-000002","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001691102-26-000009","accession_number":"0001691102-26-000009","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001727275-26-000002","accession_number":"0001727275-26-000002","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001815308-26-000006","accession_number":"0001815308-26-000006","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001827505-26-000007","accession_number":"0001827505-26-000007","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001860131-26-000010","accession_number":"0001860131-26-000010","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001899935-26-000007","accession_number":"0001899935-26-000007","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001929863-26-000002","accession_number":"0001929863-26-000002","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/4/0001959750-26-000003","accession_number":"0001959750-26-000003","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"POS AM","title":"POS AM — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/pos-am/0001193125-26-267506","accession_number":"0001193125-26-267506","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267530","accession_number":"0001193125-26-267530","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267537","accession_number":"0001193125-26-267537","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267548","accession_number":"0001193125-26-267548","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267555","accession_number":"0001193125-26-267555","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267575","accession_number":"0001193125-26-267575","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267581","accession_number":"0001193125-26-267581","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267588","accession_number":"0001193125-26-267588","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267594","accession_number":"0001193125-26-267594","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267628","accession_number":"0001193125-26-267628","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267635","accession_number":"0001193125-26-267635","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267643","accession_number":"0001193125-26-267643","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267678","accession_number":"0001193125-26-267678","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267697","accession_number":"0001193125-26-267697","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267702","accession_number":"0001193125-26-267702","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267709","accession_number":"0001193125-26-267709","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/s-8-pos/0001193125-26-267768","accession_number":"0001193125-26-267768","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"SC 14D9/A","title":"SC 14D9/A — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/sc-14d9-a/0001140361-26-024885","accession_number":"0001140361-26-024885","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"SC TO-T/A","title":"SC TO-T/A — KalVista Pharmaceuticals, Inc. — 2026-06-11","url_slug":"/sec/cik-0001348911/sc-to-t-a/0001140361-26-024887","accession_number":"0001140361-26-024887","importance":30},{"ts":"2026-06-11","kind":"sec.insider.d","reporter":"Palleiko Benjamin L","title":"CHIEF EXECUTIVE OFFICER","shares":479989,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.d","reporter":"Yea Christopher","title":"CHIEF DEVELOPMENT OFFICER","shares":229918,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.d","reporter":"Piekos Brian","title":"Chief Financial Officer","shares":21661,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.d","reporter":"Audhya Paul K.","title":"CHIEF MEDICAL OFFICER","shares":150260,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.d","reporter":"Sweeny Nicole","title":"Chief Commercial Officer","shares":59291,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.filing","form_type":"SC 14D9/A","title":"SC 14D9/A — KalVista Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001348911/sc-14d9-a/0001140361-26-023453","accession_number":"0001140361-26-023453","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"SC TO-T/A","title":"SC TO-T/A — KalVista Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001348911/sc-to-t-a/0001140361-26-023454","accession_number":"0001140361-26-023454","importance":30},{"ts":"2026-05-21","kind":"sec.13dg","reporter":"KalVista Pharmaceuticals, Inc.","shares":1249165,"percent_of_class":2.3,"security_title":"SCHEDULE 13D/A","accession_number":"0001231919-26-000523","excerpt":null,"importance":75},{"ts":"2026-05-21","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — KalVista Pharmaceuticals, Inc. — 2026-05-21","url_slug":"/sec/cik-0001348911/schedule-13d-a/0001231919-26-000523","accession_number":"0001231919-26-000523","importance":70},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-05-19","url_slug":"/sec/cik-0001348911/4/0001691102-26-000004","accession_number":"0001691102-26-000004","importance":30},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-05-19","url_slug":"/sec/cik-0001348911/4/0001860131-26-000006","accession_number":"0001860131-26-000006","importance":30},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Palleiko Benjamin L","title":"CHIEF EXECUTIVE OFFICER","shares":1129,"price_per_share":26.76,"usd_value":30212,"security_title":"Common Stock","importance":35.03021204},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Yea Christopher","title":"CHIEF DEVELOPMENT OFFICER","shares":1108,"price_per_share":26.76,"usd_value":29650,"security_title":"Common Stock","importance":35.02965008},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Audhya Paul K.","title":"CHIEF MEDICAL OFFICER","shares":1032,"price_per_share":26.76,"usd_value":27616,"security_title":"Common Stock","importance":35.02761632},{"ts":"2026-05-17","kind":"sec.insider.m","reporter":"Palleiko Benjamin L","title":"CHIEF EXECUTIVE OFFICER","shares":2419,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-17","kind":"sec.insider.m","reporter":"Audhya Paul K.","title":"CHIEF MEDICAL OFFICER","shares":2419,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-17","kind":"sec.insider.m","reporter":"Yea Christopher","title":"CHIEF DEVELOPMENT OFFICER","shares":1774,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — KalVista Pharmaceuticals, Inc. — 2026-05-15","url_slug":"/sec/cik-0001348911/schedule-13g-a/0000919574-26-003487","accession_number":"0000919574-26-003487","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"10-Q","title":"10-Q — KalVista Pharmaceuticals, Inc. — 2026-05-14","url_slug":"/sec/cik-0001348911/10-q/0001193125-26-223976","accession_number":"0001193125-26-223976","importance":45},{"ts":"2026-05-13","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — KalVista Pharmaceuticals, Inc. — 2026-05-13","url_slug":"/sec/cik-0001348911/schedule-13g/0001104659-26-060314","accession_number":"0001104659-26-060314","importance":55},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — KalVista Pharmaceuticals, Inc. — 2026-05-13","url_slug":"/sec/cik-0001348911/4/0001366244-26-000007","accession_number":"0001366244-26-000007","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"SC 14D9","title":"SC 14D9 — KalVista Pharmaceuticals, Inc. — 2026-05-13","url_slug":"/sec/cik-0001348911/sc-14d9/0001140361-26-021078","accession_number":"0001140361-26-021078","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"SC TO-T","title":"SC TO-T — KalVista Pharmaceuticals, Inc. — 2026-05-13","url_slug":"/sec/cik-0001348911/sc-to-t/0001140361-26-020935","accession_number":"0001140361-26-020935","importance":30},{"ts":"2026-05-12","kind":"sec.insider.s","reporter":"Palleiko Benjamin L","title":"CHIEF EXECUTIVE OFFICER","shares":3322,"price_per_share":26.71,"usd_value":88731,"security_title":"Common Stock","importance":35.08873062},{"ts":"2026-05-11","kind":"sec.insider.m","reporter":"Palleiko Benjamin L","title":"CHIEF EXECUTIVE OFFICER","shares":7120,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"KalVista Pharmaceuticals, Ltd.","title":"A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II","security_title":"PHASE2","status":"TERMINATED","accession_number":"NCT05055258","excerpt":"Terminated by Sponsor due to adverse events reported","importance":80}]}